In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1 data showing its insulin combo can outperform Lilly’s fast-acting insulin in keeping sugar levels low after a meal.
The trial, which recruited 24 type 1 diabetics, studied the effect of Adocia’s BioChaperone pramlintide insulin on glucose levels right after a meal. It combines insulin treatment with pramlintide — an analog of amylin, a hormone secreted along with insulin that is missing in people with type 1 diabetes. Pramlintide is stabilized using Adocia’s BioChaperone technology, which employs polymers to protect protein drugs against degradation and enhance their performance.
When compared to Eli Lilly’s fast-acting insulin, Humalog, the combination showed a 97% reduction in spikes of blood glucose levels during the first 2 hours after a meal. It proved to be comparable to separate injections of insulin (Lilly’s Humulin) and pramlintide (AstraZeneca’s Symlin).
“By mimicking the normal co-secretion of amylin and insulin with meals, this 2-in-1 combination has the potential to address the persisting unmet need for mealtime glucose control for people with diabetes,” stated Dr. Matthew Riddle, Professor of Medicine, Oregon Health & Science University.
The news comes while a legal litigation between Adocia and Eli Lilly heats up. It all started in 2017, when Eli Lilly walked out (for the second time) from an agreement for the development of Adocia’s ultra-rapid insulin. The French company had a first win at the court last month regarding an unpaid milestone worth €10M. This week, it updated another claim against Lilly based on the breaching of confidentiality, raising the amount claimed from an initial $200M to $1.8Bn. Lilly has filed counterclaims worth $188M.
Images via Shutterstock; Adocia